NBRVF (Nabriva Therapeutics) EBITDA Margin %: -466.43% (As of Jun. 2023)

What is Nabriva Therapeutics EBITDA Margin %?

Nabriva Therapeutics NBRVF 12 EBITDA Margin % is -466.43% as of Jun. 2023. GuruFocus rates NBRVF with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nabriva Therapeutics's EBITDA for the three months ended in Jun. 2023 was $-12.01 Mil. Nabriva Therapeutics's Revenue for the three months ended in Jun. 2023 was $2.57 Mil. Therefore, Nabriva Therapeutics's EBITDA margin for the quarter that ended in Jun. 2023 was -466.43%.

Nabriva Therapeutics (OTCPK:NBRVF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nabriva Therapeutics EBITDA Margin % Related Terms

Nabriva Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Nabriva Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nabriva Therapeutics EBITDA Margin % Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

-1,755.20

-1,015.99

-2,335.06

-174.24

-153.36

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBITDA Margin %	Get a 7-Day Free Trial															-117.62	-123.08	-213.67	-111.79	-466.43

NBRVF vs BXRX, INM, ADTX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Nabriva Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's EBITDA Margin % falls into.

Save Embed

12GF Score

Nabriva Therapeutics PLC NBRVF

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nabriva Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nabriva Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-54.702	/	35.668
	=	-153.36 %

Nabriva Therapeutics's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-12.006	/	2.574
	=	-466.43 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -466.43% mean?

Nabriva Therapeutics (NBRVF) has a EBITDA Margin % of -466.43% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nabriva Therapeutics and its competitors.

Is Nabriva Therapeutics' EBITDA Margin % too high?

Nabriva Therapeutics' current EBITDA Margin % is -466.43%. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Nabriva Therapeutics' EBITDA Margin % compare to BXRX and INM?

Nabriva Therapeutics' EBITDA Margin % of -466.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nabriva Therapeutics and its competitors. Nabriva Therapeutics's current EBITDA Margin % is -466.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nabriva Therapeutics stock overvalued right now?

Nabriva Therapeutics (NBRVF) has a current EBITDA Margin % of -466.43%. The current EBITDA Margin % is -466.43%. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current EBITDA Margin % is -466.43% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nabriva Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies BXRX INM ADTX CFRX RUBY SPRC DRMA AMPE NBY SCPS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

12GF Score

Get the complete analysis for NBRVF

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View NBRVF Analysis

See EBITDA Margin % data for all stocks →